Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "cells"

466 News Found

Cardinal Health boosts production of cutting-edge cancer therapy ingredient
News | April 03, 2026

Cardinal Health boosts production of cutting-edge cancer therapy ingredient

Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.


Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy
News | March 31, 2026

Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy

Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively


Novartis strikes $3 billion deal to acquire next-gen breast cancer drug
News | March 25, 2026

Novartis strikes $3 billion deal to acquire next-gen breast cancer drug

SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors


Godavari Biorefineries secures Japanese patent for antiviral compounds
R&D | March 23, 2026

Godavari Biorefineries secures Japanese patent for antiviral compounds

The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways


Biotium unveils ViaPlex 2-Color Cell Barcoding Kit to supercharge flow cytometry
News | March 20, 2026

Biotium unveils ViaPlex 2-Color Cell Barcoding Kit to supercharge flow cytometry

The kit features ViaPlex 405 Barcoding Dye for the 405 nm laser/Pacific Blue filter and ViaPlex 488 Barcoding Dye for the 488 nm laser/FITC filter


GelMEDIX partners with Catalent to advance vision-restoring cell therapies
News | March 14, 2026

GelMEDIX partners with Catalent to advance vision-restoring cell therapies

The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing


Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
Clinical Trials | March 14, 2026

Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

The early-stage study will test the drug’s safety, tolerability and biological effects in humans


Citius Oncology reports promising early trial results for therapy for gynecologic cancers
Clinical Trials | March 14, 2026

Citius Oncology reports promising early trial results for therapy for gynecologic cancers

The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR